CG Oncology stockholders elect three Class I directors, ratify EY as auditor at 2025 annual meeting

CG Oncology, Inc.

Arthur Kuan, James J. Mulé, Leonard Post elected as Class I directors to serve until 2028 annual meeting.
Ratification of Ernst & Young as independent auditor for fiscal year ending Dec 31, 2025 was approved with 69.7M votes for, 7K against.
Broker non-votes of 8.45M shares on director elections; no broker non-votes on auditor ratification.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.